

WEST

Generate Collection

Print

L5: Entry 2 of 20

File: USPT

May 7, 2002

US-PAT-NO: 6384038

DOCUMENT-IDENTIFIER: US 6384038 B1

TITLE: Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants

DATE-ISSUED: May 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rubin; Paul D.	Sudbury	MA		

US-CL-CURRENT: 514/255.04; 514/826, 514/849, 514/850, 514/853, 514/860, 514/862, 514/887

CLAIMS:

What is claimed is:

1. A method for the prophylaxis or treatment of asthma or a symptom thereof in a human which comprises administering to a human in need thereof:

(a) a therapeutically effective amount of cetirizine or a pharmaceutically acceptable salt thereof, and;

(b) a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.

2. A method for the prophylaxis or treatment of asthma or a symptom thereof in a human which comprises administering to a human, in need thereof, a composition comprising:

(a) a therapeutically effective amount of cetirizine or a pharmaceutically acceptable salt thereof;

(b) a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, selected from the group consisting of 5-lipoxygenase inhibitors, 5-lipoxygenase activating protein antagonists, and leukotriene receptor antagonists, and mixtures thereof, and;

(c) a pharmaceutically acceptable carrier or excipient.

3. The method of claim 1 or 2 further comprising administering a therapeutically effective amount of a decongestant, or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 or 2 wherein said human has asthma.

5. The method of claim 1 or 2 wherein said effective amount of cetirizine is an effective amount of racemic cetirizine.

6. The method of claim 1 or 2 wherein said cetirizine is the optically pure (+) enantiomer.

7. The method of claim 1 or 2 wherein said cetirizine is the optically pure (-) enantiomer.

WEST☐

L5: Entry 2 of 20

File: USPT

May 7, 2002

US-PAT-NO: 6384038

DOCUMENT-IDENTIFIER: US 6384038 B1

TITLE: Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants

DATE-ISSUED: May 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rubin; Paul D.	Sudbury	MA		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Sepracor Inc.	Marlborough	MA			02

APPL-NO: 09/ 059571 [PALM]

DATE FILED: April 14, 1998

INT-CL: [07] A61 K 31/495

US-CL-ISSUED: 514/255; 514/826, 514/849, 514/850, 514/853, 514/860, 514/862, 514/887

US-CL-CURRENT: 514/255.04; 514/826, 514/849, 514/850, 514/853, 514/860, 514/862, 514/887

FIELD-OF-SEARCH: 514/255, 514/826, 514/849, 514/850, 514/853, 514/860, 514/862, 514/887

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

	PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<input type="checkbox"/>	<u>4581232</u>	April 1986	Peters et al.	424/155
<input type="checkbox"/>	<u>4783465</u>	November 1988	Sunshine et al.	514/255
<input type="checkbox"/>	<u>5276044</u>	January 1994	Ambrus et al.	514/352
<input type="checkbox"/>	<u>5478941</u>	December 1995	Cossement et al.	544/383

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
780127	June 1997	EP	
WO 97/28797	August 1997	WO	
99/32125	July 1999	WO	

OTHER PUBLICATIONS

Ganse et al, "Effects of antihistamines in adult asthma: a meta-analysis of clinical trials", Eur. Respir. J. (10), pp. 2216-2224 (1997).*

Stater et al, "Second-Generation Antihistamines: a Comparative Review", Drugs 57(1), pp. 31-47 (1999).*

Baroody, F.M., et al., "Effects of Loratadine and Terfenadine on the Induced Nasal Allergic Reaction", Arch. Otolaryngol. Head and Neck Surg., 122:309-316 (1996).

F-D-C Reports, "Trade and Govt. Memos", Feb. 9, 1998.

Ku, Y., et al., "Effects of Histamine H₁ Receptor Antagonists on Action Potentialists in Guinea-Pig Isolated Papillary Muscles", Arch. Int. Pharmacodyn., 331:59-73 (1996).

Merk Index, "6340, Montelukast," p. 1070, Twelfth Edition (1996).

Physician's Desk Reference, p. 303, 474-476, 3148-3149 (1988).

Roquet, A., et al., "Combined Antagonism of Leukotriene and Histamine Produces Predominant Inhibition of Allergen-Induced Early and Late Phase Airway Obstruction in Asthmatics", Am. J. Respir. Crit. Care Med., 155:1856-1863 (1997).

Zhang, M.Q., & Timmerman, H., "Leukotriene cysLT₁ (LTD₁) receptor antagonism of H₁-antihistamines: An in vitro study", Inflamm. Res., 46(1):S93-S94 (1997).

Joelson I. Braga da Motta et al., Drug Modulation of Antigen-induced paw Oedema in Guinea-Pigs: Effects of Lipopolysaccharide, Tumor Necrosis Factor and Leucocyte Depletion, Br. J. Pharmacol. (1994), 112, 111-116.

ART-UNIT: 1614

PRIMARY-EXAMINER: Krass; Frederick

ABSTRACT:

Methods and pharmaceutical compositions employing (+) cetirizine, (-) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.

7 Claims, 0 Drawing figures